
Supplementary information

Clustering for a better prediction of type 2 diabetes mellitus

In the format provided by the
authors and unedited

Supplementary Table 1. Recent studies based on clustering strategies for deciphering the heterogeneity of (pre)diabetes mellitus

Study	Initial clustering 1/ Total number 2/ Phenotypes; 3/ Used variables)	Replication study 1/ Total number 2/ Phenotypes 3/ Used variables	Clusters	Outcomes
Wagner et al. (2021)¹	1/ <i>n</i> = 899 (including 421 participants with longitudinal data) 2/ history of prediabetes, family history of diabetes, BMI ≥ 27 kg/m ² or history of gestational diabetes 3/ glycemia during OGTT (5-point OGTT AUC), ISI (Matsuda), insulin secretion (AUC ₀₋₃₀ C-peptide / AUC ₀₋₃₀ Glucose), HDLc, liver fat content, subcutaneous fat volume, visceral fat volume, PRS for T2D (including 484,788 SNPs)	1/ <i>n</i> = 6,810 with longitudinal data 2/ exclusion of participants with prevalent or incident diabetes at baseline and those of a non-white ethnicity 3/ glycemia during OGTT (2-point OGTT AUC), ISI (Matsuda), insulin secretion (Stumvoll's 1 st phase-index), FI, fasting TG, WC, HC, BMI, HDLc	6 clusters 1: low risk 2: very low risk 3: beta-cell failure 4: low risk obese 5: high risk insulin-resistant fatty liver 6: high risk visceral fat nephropathy	- Clusters 3 , 5 and 6 associated with increased glycemia (fasting glucose, postchallenge glucose, HbA1c), lower DI, higher risk of kidney disease - Clusters 3 and 5 associated with imminent T2D risk - Clusters 5 and 6 associated with all-cause mortality - Cluster 6 associated with lower GRS for beta-cell function (according to Udler et al.) - Cluster 3 associated with higher PRS for T2D - Cluster 3 associated with the T2D-associated SNP in <i>MTNR1B</i>
Ahlqvist et al. (2018)²	1/ <i>n</i> = 8,990 with longitudinal data 2/ individuals with newly diagnosed diabetes; exclusion of patients with secondary diabetes and extreme outliers 3/ GADA, age at diagnosis, BMI, HbA1c, HOMA2-B and HOMA2-IR based on C-peptide concentrations.	1/ 3 cohorts: <i>n</i> = 1,466; <i>n</i> = 844; and <i>n</i> = 3,485 with longitudinal data 2/ individuals with diabetes; exclusion of patients with secondary diabetes and extreme outliers 3/ GADA, age at diagnosis, BMI, HbA1c, HOMA2-B and HOMA2-IR based on C-peptide concentrations.	5 clusters 1: severe autoimmune diabetes 2: severe insulin-deficient diabetes 3: severe insulin-resistant diabetes 4: mild obesity-related diabetes 5: mild age-related diabetes	- Clusters 1 and 2 associated with higher HbA1c, more frequent ketoacidosis, shortest time to sustained insulin use - Cluster 3 associated with highest risk of NAFLD, CKD and diabetic kidney disease - Cluster 2 associated with highest risk of retinopathy - Clusters 1 , 2 , 4 and 5 associated with GRS for T2D (including 64 SNPs) - Clusters 2 , 4 and 5 associated with GRS for insulin secretion (including 15 SNPs)
Udler et al. (2018)³	1/ and 2/ based on GWAS summary statistics (from MAGIC, GIANT, EGG, VATGen, ICBP, ENGAGE, CHARGE consortia) [mostly general populations] 3/ 94 independent T2D-associated SNPs and 47 diabetes-related traits	Application in: 4 cohorts including patients with T2D (<i>n</i> = 487, <i>n</i> = 509, <i>n</i> = 2,065 and <i>n</i> = 14,813)	5 clusters 1: beta-cell 2: proinsulin 3: obesity 4: lipodystrophy 5: liver/lipid	- Cluster 1 associated with decreased CIR, DI, Ins30 adj BMI, HOMA-B, and increased PI adj for FI; T2D-associated SNPs in <i>MTNR1B</i> , <i>HHEX</i> , <i>TCF7L2</i> , <i>SLC30A8</i> , <i>HNF1A</i> , and <i>HNF1B</i> ; increased risk for ischemic stroke; in T2D: decreased BMI, % body fat, fasting C-peptide - Cluster 2 associated with decreased Ins30, HOMA-B, PI adj for FI; T2D-associated SNPs in <i>ARAP1/STARD10</i> and <i>SPRY2</i> ; increased blood pressure; in T2D: decreased BMI, fasting C-peptide - Cluster 3 associated with increased WC, HC, BMI, and % body fat; T2D-associated SNPs in <i>FTO</i> and <i>MC4R</i> ; in T2D, increased BMI, % body fat, HC, and WC - Cluster 4 associated with decreased ISI adj BMI, adiponectin, HDLc, and increased TG; increased UACR; in T2D: decreased BMI, % body fat, HDLc - Cluster 5 associated with decreased TG, palmitoleic acid, urate, and linolenic acid, and increased gamma-linolenic acid; reduced eGFR; in T2D: decreased TG - Individuals with T2D and a GRS uniquely at the top 10th of one cluster as a group had representative trait characteristics distinguishing them from all other individuals with T2D

AUC, area under the curve; **BMI**, body mass index; **CIR**, corrected insulin response; **CKD**, chronic kidney disease; **DI**, disposition index; **eGFR**, estimated glomerular filtration rate; **FI**, fasting insulin; **GADA**, glutamic acid decarboxylase antibodies; **GRS**, genetic risk score; **GWAS**, genome-wide association study; **HbA1c**, glycated hemoglobin A1c; **HC**, hip circumference; **HDLc**, high-density lipoprotein cholesterol; **HOMA-B**, homoeostasis model assessment estimate of beta-cell function; **HOMA2-B**, homoeostasis model assessment 2 estimate of beta-cell function; **HOMA2-IR**, homoeostasis model assessment 2 estimate of insulin resistance; **Ins30 adj BMI**, insulin at 30 minutes of OGTT adjusted for BMI; **ISI adj BMI**, insulin sensitivity index adjusted form BMI; **NAFLD**, non-alcoholic fatty liver disease; **OGTT**, oral glucose tolerance test; **PI adj FI**, proinsulin levels adjusted for fasting insulin; **PRS**, polygenic risk score; **SNP**, single nucleotide polymorphism; **T2D**, type 2 diabetes; **TG**, triglycerides; **UACR**, urine albumin-creatinine ratio; **WC**, waist circumference.

References

1. Wagner, R. *et al.* Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. *Nat Med* (2021) doi:10.1038/s41591-020-1116-9.
2. Ahlqvist, E. *et al.* Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* **6**, 361–369 (2018).
3. Udler, M. S. *et al.* Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. *PLOS Medicine* **15**, e1002654 (2018).